17713163

Source:http://linkedlifedata.com/resource/pubmed/id/17713163

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0085415, umls-concept:C0229671, umls-concept:C0441889, umls-concept:C0524910, umls-concept:C0681842
pubmed:issue	5
pubmed:dateCreated	2007-8-23
pubmed:abstractText	To analyse the association between serum alpha-foetoprotein (AFP) levels and sustained virological response (SVR) in treated patients.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9815705
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/AFP protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents, http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha, http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols, http://linkedlifedata.com/resource/pubmed/chemical/Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Ribavirin, http://linkedlifedata.com/resource/pubmed/chemical/alpha-Fetoproteins, http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2a, http://linkedlifedata.com/resource/pubmed/chemical/peginterferon alfa-2a
pubmed:status	MEDLINE
pubmed:issn	1359-6535
pubmed:author	pubmed-author:Abdel-HamidMohamedM, pubmed-author:AbobakrHasanH, pubmed-author:BedossaPierreP, pubmed-author:El HoseinyMostafaM, pubmed-author:EsmatGamalG, pubmed-author:FontanetArnaudA, pubmed-author:GadRita RaafatRR, pubmed-author:MalesSylviaS, pubmed-author:MohamedAnwarA, pubmed-author:MohamedMostafa KMK, pubmed-author:PolStanislasS, pubmed-author:RekacewiczClaireC, pubmed-author:ZalataKhaledK
pubmed:issnType	Print
pubmed:volume	12
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	797-803
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:17713163-Administration, Oral, pubmed-meshheading:17713163-Adult, pubmed-meshheading:17713163-Antiviral Agents, pubmed-meshheading:17713163-Biological Markers, pubmed-meshheading:17713163-Drug Administration Schedule, pubmed-meshheading:17713163-Drug Therapy, Combination, pubmed-meshheading:17713163-Egypt, pubmed-meshheading:17713163-Female, pubmed-meshheading:17713163-Hepatitis C, Chronic, pubmed-meshheading:17713163-Humans, pubmed-meshheading:17713163-Injections, Subcutaneous, pubmed-meshheading:17713163-Interferon-alpha, pubmed-meshheading:17713163-Linear Models, pubmed-meshheading:17713163-Male, pubmed-meshheading:17713163-Middle Aged, pubmed-meshheading:17713163-Odds Ratio, pubmed-meshheading:17713163-Patient Selection, pubmed-meshheading:17713163-Polyethylene Glycols, pubmed-meshheading:17713163-Proteins, pubmed-meshheading:17713163-Recombinant Proteins, pubmed-meshheading:17713163-Ribavirin, pubmed-meshheading:17713163-Time Factors, pubmed-meshheading:17713163-Treatment Outcome, pubmed-meshheading:17713163-Viral Load, pubmed-meshheading:17713163-Virus Replication, pubmed-meshheading:17713163-alpha-Fetoproteins
pubmed:year	2007
pubmed:articleTitle	Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C.
pubmed:affiliation	Unité d'Epidémiologie des Maladies Emergentes, Institut Pasteur, Paris, France.
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Multicenter Study